Technical Analysis for ELVN - Enliven Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 5.79% | |
Calm After Storm | Range Contraction | 5.79% | |
NR7 | Range Contraction | 5.79% | |
Inside Day | Range Contraction | 5.79% | |
Wide Bands | Range Expansion | 5.79% | |
Overbought Stochastic | Strength | 5.79% | |
Stochastic Sell Signal | Bearish | 4.78% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.78% |
Alert | Time |
---|---|
Non-ADX 1,2,3,4 Pullback Entry | about 14 hours ago |
Rose Above Previous Day's High | about 14 hours ago |
Up 5% | about 14 hours ago |
Possible NR7 | about 16 hours ago |
Possible Inside Day | about 16 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Her2 Chronic Myeloid Leukemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 23.98 |
52 Week Low | 9.84 |
Average Volume | 139,207 |
200-Day Moving Average | 15.19 |
50-Day Moving Average | 15.72 |
20-Day Moving Average | 15.65 |
10-Day Moving Average | 16.35 |
Average True Range | 1.65 |
RSI (14) | 61.09 |
ADX | 23.86 |
+DI | 25.84 |
-DI | 16.56 |
Chandelier Exit (Long, 3 ATRs) | 14.56 |
Chandelier Exit (Short, 3 ATRs) | 15.84 |
Upper Bollinger Bands | 20.43 |
Lower Bollinger Band | 10.87 |
Percent B (%b) | 0.81 |
BandWidth | 61.12 |
MACD Line | 0.70 |
MACD Signal Line | 0.22 |
MACD Histogram | 0.4718 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 20.59 | ||||
Resistance 3 (R3) | 20.44 | 19.62 | 20.27 | ||
Resistance 2 (R2) | 19.62 | 19.12 | 19.70 | 20.16 | |
Resistance 1 (R1) | 19.13 | 18.81 | 19.37 | 19.28 | 20.05 |
Pivot Point | 18.31 | 18.31 | 18.44 | 18.39 | 18.31 |
Support 1 (S1) | 17.82 | 17.81 | 18.07 | 17.98 | 17.21 |
Support 2 (S2) | 17.00 | 17.50 | 17.08 | 17.10 | |
Support 3 (S3) | 16.51 | 17.00 | 16.99 | ||
Support 4 (S4) | 16.67 |